EAC will showcase abstract presentations from allergists, immunologists and fellows-in-training. We invite you to participate by submitting your clinical research for review by our Abstract Committee. When preparing your abstract, organize it into a statement of purpose, statement of methods, and summary of results in sufficient detail to support the conclusion reached.
If your abstract is accepted for the conference, you will be assigned a specific day (Friday or Saturday) to present your findings.
All abstracts will have the option to be published in Allergy & Asthma Proceedings.
Abstract submission deadline:
Monday, April 6, 2026
Abstract application:
Coming soon
Abstract fees:
Coming soon
Abstract instructions:
- Size for poster display: 4 feet high by 6 feet long
- The abstract must adequately describe the objectives, methods, results, and conclusions so that the Abstract Committee may evaluate the quality of the work and proposed presentation.
- The abstract title should fully reflect the content of the abstract body.
- A structured abstract format is required:
o Title
o Author line (affiliations will not be printed in program booklet)
o Introduction (background and purpose of the project/study)
o Methods (study design, techniques)
o Results (summary of data)
o Conclusions
o Funding if appropriate
- Illustrations and tables will not be printed in the program booklet but may be included in your presentation poster.
- Supplementary data is not accepted under any circumstances.
- Abbreviations may be used in the abstract if such abbreviations are defined at their first mention.
- The abstract length is limited to 300 words.
- Abstracts must be submitted in a word.DOC format.
- Font size 12, New Times Roman, title and headings only in bold
- Authors are to be listed by First name, Last name, Highest degree (ie: John Smith, MD). Affiliations should not be included as they will not be printed in the program book, but they are allowed in your final abstract presentation.
- Authors are encouraged, but not required, to submit for peer review and publication, any subsequent full-length manuscripts which derive from the submitted abstract.
- Each abstract submission must specify a corresponding author, to whom all correspondence about the abstract will be directed.
- The presenter of each accepted abstract must register for EAC.
- Wherever possible, non-commercial (generic) names must be used in all abstracts and posters. The Abstract Committee may request a revised submission of the abstract to enforce compliance with this ACCME requirement.
- All authors must agree to disclose all non-FDA approved use of FDA approved drugs in the submission email only. No further disclosure is needed.
- The authors must accept sole responsibility for the statements in their submitted abstract.